undamentalytics Newsletter
Sign in

Agape ATP Corp (ATPC) stock

Add to watchlist

Add holding +

NASDAQ: ATPC Nasdaq Health Care Services

E Fundamentals grade

Agape ATP Corp is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Agape ATP Corp is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Agape ATP Corp valuation: adjust assumptions and compare models →

Value diary

Our note on each quarter Agape ATP files

Where Agape ATP stands after its latest 10-Q

Agape ATP has little or no product revenue yet; it used $1m of cash in the twelve months to June 2026. That puts it 34 of 37 for growth among the health care services companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our model value for Agape ATP is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Agape ATP Corp's trailing-twelve-month revenue fell 20.3% year on year, with a free-cash-flow margin of -84.7%. Where it lags: change in growth rate of -37.0pp ranks 40 of 41 health care services companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -20.3% (-37.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 53.3% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 20.3% over the last 12 months.
  • Growth slowing. The growth rate is 37.0 points lower than a quarter earlier.
  • Loss-making. Operating margin is -271.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 82.0 points on a year ago.
  • Burning cash. Free cash flow was -84.7% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 308% and a beta of -0.6 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Revenue
$0m, down 76.6% on a year earlier

Agape ATP's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.0%
  • 1 week-3.6%
  • 1 month-36.0%
  • This year-75.3%
  • 1 year-97.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2M
Operating margin
-271.4%
Net margin
-100.2%

Growth

Revenue growth
−20.3%
Change in growth rate
−37.0 pts

Cash

Free cash flow (TTM)
-$975,857
FCF margin
-84.7%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for ATPC from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Agape ATP Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Agape ATP Corp as an operating company, with every model that fits that kind of business. Cost of equity 7.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.54 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$0.4–$2.7 Left out: out of range vs price (0.02x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Agape ATP Corp with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025
Share price$639.00$59.00$5.35
Market value$484.5bn$46m$4m
+ Net debt (− = net cash)−$5m−$2m−$89651
Enterprise value$484.4bn$44m$4m
Multiples
Price / sales n/m34.7x2.8x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard Agape ATP's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -10.8% of total assets over 9 years.

  • Pricing power 11 / 20

    Gross margin has been a median 57.2%, moving by 26.0 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -160.3%; its worst year was -271.4%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 6 years, at a median -95.0% of revenue.

  • Discipline 15 / 20

    The diluted share count fell 79.6% over five years.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (38 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Agape ATP Corp: too few analysts cover it.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
0.14
at average volume
Short interest, 1 month
−70%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
2.0%
of shares
Employees
18
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202420252026 to date
Return
ATPC−91%−91%−75%
Industry peers (median)−6%−6%+15%
S&P 500+25%+18%+11%
Months that ended higher
ATPC25%42%27%
S&P 50075%75%46%
Largest fall from a high during the year
ATPC−91%−97%−78%
S&P 500−8%−19%−9%

Worst fall since September 11, 2023: 100% from October 5, 2023 to November 2, 2026. Getting back needed a 1363536% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.32 – $69.00
From 52-week high
−98.1%
vs 50-day average
−35.4%
vs 200-day average
−50.0%
Volatility (1 year)
308%
Beta vs S&P 500
-0.64

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Agape ATP Corp
$1.1M $1.2M $1.3M $1.4M $1.5M $1.6M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.4M Revenue (TTM), FY23 Q4: $1.4M Revenue (TTM), FY24 Q1: $1.4M Revenue (TTM), FY24 Q2: $1.4M Revenue (TTM), FY24 Q3: $1.4M Revenue (TTM), FY24 Q4: $1.3M Revenue (TTM), FY25 Q1: $1.3M Revenue (TTM), FY25 Q2: $1.4M Revenue (TTM), FY25 Q3: $1.5M Revenue (TTM), FY25 Q4: $1.5M Revenue (TTM), FY26 Q1: $1.5M Revenue (TTM), FY26 Q2: $1.2M $1.2M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.4M
FY23 Q4 $1.4M
FY24 Q1 $1.4M
FY24 Q2 $1.4M
FY24 Q3 $1.4M
FY24 Q4 $1.3M
FY25 Q1 $1.3M
FY25 Q2 $1.4M
FY25 Q3 $1.5M
FY25 Q4 $1.5M
FY26 Q1 $1.5M
FY26 Q2 $1.2M
Revenue growth, TTM YoY Agape ATP Corp
-40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -15.0% Revenue growth, TTM YoY, FY23 Q4: -22.9% Revenue growth, TTM YoY, FY24 Q1: -25.1% Revenue growth, TTM YoY, FY24 Q2: -20.6% Revenue growth, TTM YoY, FY24 Q3: -5.1% Revenue growth, TTM YoY, FY24 Q4: -7.6% Revenue growth, TTM YoY, FY25 Q1: -5.5% Revenue growth, TTM YoY, FY25 Q2: 4.9% Revenue growth, TTM YoY, FY25 Q3: 9.7% Revenue growth, TTM YoY, FY25 Q4: 15.2% Revenue growth, TTM YoY, FY26 Q1: 16.7% Revenue growth, TTM YoY, FY26 Q2: -20.3% -20.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -15.0%
FY23 Q4 -22.9%
FY24 Q1 -25.1%
FY24 Q2 -20.6%
FY24 Q3 -5.1%
FY24 Q4 -7.6%
FY25 Q1 -5.5%
FY25 Q2 4.9%
FY25 Q3 9.7%
FY25 Q4 15.2%
FY26 Q1 16.7%
FY26 Q2 -20.3%
Operating margin (TTM) Agape ATP Corp
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -132.6% Operating margin (TTM), FY23 Q4: -150.0% Operating margin (TTM), FY24 Q1: -176.5% Operating margin (TTM), FY24 Q2: -182.2% Operating margin (TTM), FY24 Q3: -202.5% Operating margin (TTM), FY24 Q4: -194.5% Operating margin (TTM), FY25 Q1: -198.8% Operating margin (TTM), FY25 Q2: -189.4% Operating margin (TTM), FY25 Q3: -188.0% Operating margin (TTM), FY25 Q4: -212.6% Operating margin (TTM), FY26 Q1: -212.0% Operating margin (TTM), FY26 Q2: -271.4% -271.4%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -132.6%
FY23 Q4 -150.0%
FY24 Q1 -176.5%
FY24 Q2 -182.2%
FY24 Q3 -202.5%
FY24 Q4 -194.5%
FY25 Q1 -198.8%
FY25 Q2 -189.4%
FY25 Q3 -188.0%
FY25 Q4 -212.6%
FY26 Q1 -212.0%
FY26 Q2 -271.4%
FCF margin (TTM) Agape ATP Corp
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -80.1% FCF margin (TTM), FY23 Q4: -144.8% FCF margin (TTM), FY24 Q1: -221.8% FCF margin (TTM), FY24 Q2: -215.8% FCF margin (TTM), FY24 Q3: -231.5% FCF margin (TTM), FY24 Q4: -210.1% FCF margin (TTM), FY25 Q1: -231.2% FCF margin (TTM), FY25 Q2: -211.8% FCF margin (TTM), FY25 Q3: -194.5% FCF margin (TTM), FY25 Q4: -159.6% FCF margin (TTM), FY26 Q1: -90.3% FCF margin (TTM), FY26 Q2: -84.7% -84.7%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -80.1%
FY23 Q4 -144.8%
FY24 Q1 -221.8%
FY24 Q2 -215.8%
FY24 Q3 -231.5%
FY24 Q4 -210.1%
FY25 Q1 -231.2%
FY25 Q2 -211.8%
FY25 Q3 -194.5%
FY25 Q4 -159.6%
FY26 Q1 -90.3%
FY26 Q2 -84.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Jun 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 487 1,290 3,453 1,017 1,857 1,431 1,323 1,524 1,152
Gross profit 46 89 2,677 720 1,191 937 759 838 644
EBITDA — — −157 −1,783 −1,462 −2,076 −2,521 −3,236 −3,122
Operating income −234 −315 −158 −1,859 −1,533 −2,147 −2,573 −3,257 −3,128
Net income −130 −716 355 −2,524 −1,687 −2,102 −2,470 −2,280 −1,155
Diluted EPS $0.00 $0.00 $0.00 −$0.00 −$0.00 −$2.75 −$3.17 −$2.85 —
Growth (year on year)
Revenue — +164.9% +167.6% −70.5% +82.6% −22.9% −7.6% +15.2% −20.3%
Net income — — — −811.5% — — — — —
Margins
Gross margin 9.4% 6.9% 77.5% 70.8% 64.1% 65.4% 57.4% 55.0% 55.9%
EBITDA margin — — −4.5% −175.3% −78.7% −145.1% −190.6% −212.3% −270.9%
Operating margin −48.1% −24.4% −4.6% −182.8% −82.6% −150.0% −194.5% −213.7% −271.4%
Net margin −26.8% −55.5% 10.3% −248.2% −90.9% −146.9% −186.8% −149.6% −100.2%
Free-cash-flow margin — — −16.3% −83.6% −43.7% −139.9% −206.1% −158.3% —
Cash flow
Cash from operations −348 −704 −558 −846 −812 −2,002 −2,726 −2,413 −970
Capital spending — — 5 4 0 0 0 0 —
Free cash flow — — −563 −850 −812 −2,002 −2,726 −2,413 —
Balance sheet
Cash — 2,744 3,518 2,598 1,438 4,832 2,040 90 45
Total debt 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) — −2,744 −3,518 −2,598 −1,438 −4,832 −2,040 −90 −45
Diluted shares 3,730m 3,763m 3,764m 3,762m 878m 758m — — —
Returned to shareholders
Buybacks — — — — — 94 — — —
Total returned — — — — — 94 — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $25m
Short-term assets $25mLonger-term assets $0m
What it owes, and who funded it · $25m
Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $22m
  • Short-term assets cover short-term liabilities $25m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $25m short-term assets against $34,117 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Agape ATP Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated ATPC MGRX AHG AMS CCEL HAO Median
Revenue, last 12 months $1m $315227 $14m $30m $31m $55m $1.2bn
Revenue growth, last 12 months −20.3% −38.9% −6.4% 4.0% −2.0% 67.1% 7.3%
Revenue growth, 3-year average −12.8% — — 14.3% −0.1% — 11.3%
Revenue growth, latest quarter −76.6% −59.1% — 19.2% −0.0% — 8.5%
Gross margin 55.9% 54.4% −0.1% 17.1% 78.5% 1.1% 27.9%
Operating margin −271.4% <−999% −149.7% −11.8% 0.6% −17.6% 2.3%
Operating margin, 3-year average −214.3% <−999% −44.4% −8.5% −8.4% — 2.3%
Net margin −100.2% <−999% −135.0% −5.8% −6.2% −17.4% 1.2%
Cash from operations / revenue −84.2% <−999% −92.5% 17.6% 15.8% −4.7% 6.1%
Free-cash-flow margin −84.7% <−999% −92.5% 11.6% 14.9% −5.2% 5.1%
Free-cash-flow margin, 3-year average −170.7% <−999% — −14.8% 14.7% — 3.6%
Stock pay / revenue — 688.0% 6.5% 1.3% 1.1% 0.2% 1.1%
Change in share count −53.3% — 153.5% 0.4% −1.4% >999% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -20.3% 7.3% 37 of 41
Change in growth rate Growth -37.0pp +1.1pp 40 of 41
Gross margin Profitability 55.9% 29.0% 7 of 27
Operating margin Profitability -271.4% 2.6% 39 of 40
Net margin Profitability -100.2% 1.2% 39 of 41
Free-cash-flow margin Cash generation -84.7% 5.1% 38 of 40

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Skin Care Health and Wellness $1.4M 90.8% ▲ 8.2%
Green Energy $139,727 9.2% ▲ 226.7%
Products and services
Line of business Revenue Share YoY
Products $1.4M 88.6% ▲ 21.5%
Product Health Therapies $912,239 67.3% ▼ 0.1%
Skin Care and Health Care Products $231,721 17.1% ▲ 948.9%
Green Energy $139,727 10.3% ▲ 226.7%
Energized Mineral Concentrate $59,024 4.4% ▲ 35.7%
LIVO5 $7,931 0.6% ▼ 89.6%
Health and Wellness Services $169,299 11.1% ▼ 18.4%
Mix Soy Protein Isolate Powderwith Black Sesame $2,462 0.2% ▼ 66.5%
Soy Protein Isolate Powder $1,859 0.1% ▼ 80.1%

From Agape ATP Corp's 10-K filed April 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

13F filings for June 30, 2026
Reported value
$309,989
Institutions reporting
3
Shares held vs prior quarter
▲ 299.2%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $174,000 59K 56.1% New
Jane Street Group, LLC $135,965 46K 43.9% ▲ 94.1%
UBS Group AG $24 0K 0.0% ▼ 99.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Agape ATP Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Agape ATP Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Agape ATP Corp in brief

What does Agape ATP Corp do?
Agape ATP Corp is a US-listed company in the health care services industry. Its financial year ends in December.
What is Agape ATP Corp's stock ticker?
Agape ATP Corp trades under the ticker ATPC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Agape ATP Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Agape ATP Corp reported revenue of $1.2M, 20.3% lower than a year earlier, according to its SEC filings.
What is Agape ATP Corp's free cash flow?
Agape ATP Corp's free-cash-flow margin is -84.7% of revenue over the trailing twelve months, ranking 38 of the 40 health care services companies we cover.
Who are Agape ATP Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Jane Street Group, LLC and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Agape ATP Corp's market cap?
On December 31, 2025, Agape ATP Corp's market capitalisation was about $4.3M and net debt of -$89,651. Market figures come from third-party market data and may be delayed.
Who are Agape ATP Corp's competitors?
In our Health Care Services peer group, the companies closest to Agape ATP Corp are Mangoceuticals, Inc., Akso Health Group, American Shared Hospital Services, Cryo Cell International Inc and Haoxi Health Technology Ltd. The side-by-side comparison below sets their revenue, margins and growth against Agape ATP Corp's.